Nuvation Bio Inc. (NUVB) News
Latest headlines that mention NUVB, newest first · each headline opens the original publisher
- Last price
- $4.85
- Day change
- +1.68%
- Next earnings
- 2026-11-02
NUVB headlines
latest coverageIBTROZI revenue hit $23.2 million with 85% of new patient starts in first-line setting.
This oncology biotech advancing targeted therapies reported a notable insider sale amid ongoing clinical-stage development.
Clinical-stage biotech Nuvation Bio, focused on oncology therapeutics, reported a recent insider buy amid a year of sharp share price gains.
NUVB news alerts
Get an alert by email or push when a new headline mentions NUVB.
More news
News headlines aggregated from third-party publishers via public RSS feeds and tagged with the tickers they mention. Frenzy Capital does not publish or endorse the content; clicking a headline opens the original publisher in a new tab.